Monte Rosa Therapeutics Inc

NASDAQ GLUE

Download Data

Monte Rosa Therapeutics Inc Cash Flow Coverage Ratio 1 year YoY Change (%) for the quarter ending December 31, 2023: 181.42%

Monte Rosa Therapeutics Inc Cash Flow Coverage Ratio 1 year YoY Change (%) is 181.42% for the quarter ending December 31, 2023, a 87.33% change year over year. The cash flow coverage ratio evaluates a company's ability to cover its interest expense with its operating cash flow after deducting capital expenditures. It is calculated by dividing the difference between operating cash flow and capital expenditures by interest expense. This ratio indicates the company's ability to generate enough cash flow to service its interest payments. A higher ratio signifies better coverage and financial stability. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Monte Rosa Therapeutics Inc Cash Flow Coverage Ratio for the quarter ending March 31, 2023 was 34.85, a 117.85% change year over year.
  • Monte Rosa Therapeutics Inc Cash Flow Coverage Ratio for the quarter ending March 31, 2022 was -195.24, a 92.69% change year over year.
  • Monte Rosa Therapeutics Inc Cash Flow Coverage Ratio for the quarter ending March 31, 2021 was -2,672.00, a -136.53% change year over year.
  • Monte Rosa Therapeutics Inc Cash Flow Coverage Ratio for the quarter ending March 31, 2020 was -1,129.67.
NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO Dr. Markus Warmuth M.D.
IPO Date June 24, 2021
Location United States
Headquarters 645 Summer Street, Boston, MA, United States, 02210
Employees 130
Sector Healthcare
Industry Biotechnology
Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Similar companies

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

STOK

Stoke Therapeutics Inc

NA

NA

GRCL

Gracell Biotechnologies Inc.

NA

NA

THRX

Theseus Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email